Novartis Pharma AG
Prepay
Funding for your BMC & SpringerOpen article processing charges (APCs)
As an affiliated author, your APC could be funded by our institution’s BMC and SpringerOpen membership fund.
Please follow the submission guidelines to benefit from this membership.
Novartis Pharma AG's Articles
Page 1 of 30
-
Citation: Acta Neuropathologica Communications 2025 13:3
-
Correction: Forced randomization: the what, why, and how
Citation: BMC Medical Research Methodology 2024 24:286 -
Forced randomization: the what, why, and how
Citation: BMC Medical Research Methodology 2024 24:234 -
Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting
Citation: Advances in Rheumatology 2024 64:34 -
Virtual health and care: six steps for inclusive policymaking
Citation: BMC Global and Public Health 2024 2:19 -
Developing generic templates to shape the future for conducting integrated research platform trials
Citation: Trials 2024 25:204 -
Pocket Crafter: a 3D generative modeling based workflow for the rapid generation of hit molecules in drug discovery
Citation: Journal of Cheminformatics 2024 16:33 -
Selecting a randomization method for a multi-center clinical trial with stochastic recruitment considerations
Citation: BMC Medical Research Methodology 2024 24:52 -
Correlative light-electron microscopy methods to characterize the ultrastructural features of the replicative and dormant liver stages of Plasmodium parasites
Citation: Malaria Journal 2024 23:53 -
SIMPD: an algorithm for generating simulated time splits for validating machine learning approaches
Citation: Journal of Cheminformatics 2023 15:119 -
Estimated distribution of malaria cases among children in sub-Saharan Africa by specified age categories using data from the Global Burden of Diseases 2019
Citation: Malaria Journal 2023 22:371 -
Young patients’ involvement in a composite endpoint method development on acceptability for paediatric oral dosage forms
Citation: Research Involvement and Engagement 2023 9:108 -
Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis
Citation: Journal of Neuroinflammation 2023 20:194 -
Explaining compound activity predictions with a substructure-aware loss for graph neural networks
Citation: Journal of Cheminformatics 2023 15:67 -
A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
Citation: Cost Effectiveness and Resource Allocation 2023 21:34 -
Wdr5 is essential for fetal erythropoiesis and hematopoiesis
Citation: Experimental Hematology & Oncology 2023 12:39 -
The burden of nonalcoholic steatohepatitis (NASH) in the United States
Citation: BMC Gastroenterology 2023 23:109 -
Are there socioeconomic inequalities in polypharmacy among older people? A systematic review and meta-analysis
Citation: BMC Geriatrics 2023 23:149 -
Insulin-like growth factor-1 receptor controls the function of CNS-resident macrophages and their contribution to neuroinflammation
Citation: Acta Neuropathologica Communications 2023 11:35 -
Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease
Citation: Alzheimer's Research & Therapy 2023 15:45